Quince Therapeutics’ lead asset eDSP failed to meet the primary or secondary endpoints in the pivotal NEAT trial.

Phase 3 trial results show levacetylleucine improves SARA scores in patients with the rare disorder ataxia-telangiectasia.

Scientists at Johns Hopkins have uncovered a surprising new way to influence brain activity by targeting a long-mysterious class of proteins linked to anxiety, schizophrenia, and movement disorders.

New research suggests that the commonly-prescribed antiviral drug, oseltamivir, marketed as ‘Tamiflu’, does not cause serious neuropsychiatric symptoms, and that these symptoms are instead caused by ...

If approved, levacetylleucine could become the first therapy on the market for ataxia-telangiectasia.

Quince Therapeutics’ novel method of delivering steroids in a patient’s own red blood cells has turned out to be a bust in ataxia-telangiectasia (A-T), a rare inherited disorder. | Quince Therapeutics ...

Johns Hopkins scientists reveal that “inactive” GluD brain proteins regulate neuronal communication and open up new ...

As IntraBio works to grow the global treatment market for Aqneursa in Niemann-Pick disease type C, the company is already ...

SGT-212 has received FDA Fast Track, Rare Pediatric Disease and Orphan Drug designations - - Dosing of the first participant in the Phase 1b FALCON trial has been completed, with initial data expected ...

The Department for Work and Pensions has published the complete list of 178 medical conditions that qualify for Personal ...

The 2026 edition of Detroit's Movement electronic music festival will feature 115-plus acts led by headliners Carl Cox, Dom ...

Detroit’s Movement Music Festival has released its complete lineup, including more than 115 artists set to perform at Hart Plaza over Memorial Day Weekend. Headliners Sara Landry and Dom Dolla join ...